59 related articles for article (PubMed ID: 10682110)
1. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag.
Cappelli G; Bandiani G; Cancarini GC; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
Adv Perit Dial; 1999; 15():238-42. PubMed ID: 10682110
[TBL] [Abstract][Full Text] [Related]
2. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
3. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
4. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
6. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
8. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.
Lee HY; Choi HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Kim MJ; Shin SK
Nephrol Dial Transplant; 2006 Oct; 21(10):2893-9. PubMed ID: 16957012
[TBL] [Abstract][Full Text] [Related]
9. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
10. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid.
Simonsen O; Wieslander A; Landgren C; Rippe B
Adv Perit Dial; 1996; 12():156-60. PubMed ID: 8865892
[TBL] [Abstract][Full Text] [Related]
11. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
Haag-Weber M
Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
[TBL] [Abstract][Full Text] [Related]
12. Cell-free DNA in the peritoneal effluent of peritoneal dialysis solutions.
Pajek J; Kveder R; Gucek A; Skoberne A; Bren A; Bucar M; Cerne D; Lukac-Bajalo J
Ther Apher Dial; 2010 Feb; 14(1):20-6. PubMed ID: 20438516
[TBL] [Abstract][Full Text] [Related]
13. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
[TBL] [Abstract][Full Text] [Related]
14. Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
Chang JM; Lin SP; Lai YH; Chen HC
Am J Nephrol; 2007; 27(2):206-11. PubMed ID: 17377374
[TBL] [Abstract][Full Text] [Related]
15. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
16. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
Zeier M; Schwenger V; Deppisch R; Haug U; Weigel K; Bahner U; Wanner C; Schneider H; Henle T; Ritz E
Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796
[TBL] [Abstract][Full Text] [Related]
17. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
18. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
19. Influence of dialysis duration, peritoneal transport parameters, and gender on effluent CA125 concentration in patients on peritoneal dialysis.
Mojahedi MJ; Hami M; Shakeri MT; Hekmat R
Iran J Kidney Dis; 2007 Oct; 1(2):78-81. PubMed ID: 19363281
[TBL] [Abstract][Full Text] [Related]
20. Time to reconsider saline as the ideal rinsing solution during abdominal surgery.
Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG
Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
